BX Swiss TOP 30 CHF
1.275,78
PKT
-7,80
PKT
-0,61
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
Datum | Rating | Analyst | |
---|---|---|---|
07.10.05 | Swiss Life neutral | WestLB | |
11.10.05 | Novartis buy | Jyske Bank | |
06.10.05 | Swiss Life buy | Deutsche Bank | |
06.10.05 | Swiss Life neutral | HypoVereinsbank | |
06.10.05 | Swiss Life kaufen | Nord LB | |
06.10.05 | Swiss Life sell | Merck Finck & Co | |
06.10.05 | Swiss Life Markertperformer | LB Rheinland-Pfalz | |
06.10.05 | Novartis | Zürcher Kantonalbank | |
05.10.05 | Novartis neutral | Susquehanna Financial | |
04.10.05 | Novartis Neutral | Susquehanna Financial | |
03.10.05 | Novartis buy | Deutsche Bank | |
03.10.05 | Roche buy | Deutsche Bank | |
04.10.05 | Nestlé overweight | Morgan Stanley | |
04.10.05 | Novartis market perform | Piper Jaffray | |
06.10.05 | Swisscom neutral | Credit Suisse First Boston | |
30.09.05 | Novartis | DZ-Bank | |
30.09.05 | Novartis overweight | Prudential Financial | |
30.09.05 | Swiss Life Marketperformer | LB Rheinland-Pfalz | |
30.09.05 | Novartis outperform | WestLB | |
28.09.05 | Nestlé akkumulieren | Independent Research | |
28.09.05 | Adecco SA equal-weight | Morgan Stanley | |
28.09.05 | UBS akkumulieren | Independent Research | |
23.09.05 | Novartis | DZ-Bank | |
27.09.05 | Novartis buy | Jyske Bank | |
23.09.05 | Novartis outperform | HypoVereinsbank | |
22.09.05 | Swiss Life | Focus Money | |
21.09.05 | Novartis neutral | Bank Sarasin & Cie | |
22.09.05 | Novartis kaufen | Helaba Trust | |
21.09.05 | Novartis akkumulieren | Independent Research | |
22.09.05 | Holcim | Helaba Trust | |
20.09.05 | Novartis akkumulieren | Independent Research | |
16.09.05 | Zurich Insurance halten | Helaba Trust | |
16.09.05 | Novartis | DZ-Bank | |
16.09.05 | Holcim kaufen | Helaba Trust | |
16.09.05 | Holcim verkaufen | Helaba Trust | |
16.09.05 | Lonza overweight | JP Morgan | |
20.09.05 | Novartis buy | Jyske Bank | |
15.09.05 | Novartis halten | Wertpapier | |
15.09.05 | Zurich Insurance outperform | WestLB | |
14.09.05 | Richemont outperform | Goldman Sachs |